James E. Galen
21Patents
5h-index
14Co-inventors
66Inventor score
Filing activity: Dec 2, 1998 → Sep 29, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6413768B1 | Expression plasmids | Human Necessities | 21 | Expired |
| US6969513B2 | Plasmid maintenance system for antigen delivery | Emerging Cross-Sectional Technologies | 19 | Expired |
| US7056700B2 | Use of ClyA hemolysin for excretion of proteins | Emerging Cross-Sectional Technologies | 18 | Expired |
| US6703233B1 | Plasmid maintenance system for antigen delivery | Emerging Cross-Sectional Technologies | 16 | Expired |
| US10046040B2 | Multivalent live vector vaccine against Clostridium difficile-associated disease | Emerging Cross-Sectional Technologies | 9 | Active |
| US8137930B2 | Attenuated Salmonella enterica serovar paratyphi A and uses thereof | Emerging Cross-Sectional Technologies | 4 | Active |
| US7459161B2 | Methods for eliciting an immune response using cytolysin and hemolysin fusion proteins | Emerging Cross-Sectional Technologies | 4 | Active |
| US7141408B2 | Plasmid maintenance system for antigen delivery | Emerging Cross-Sectional Technologies | 3 | Expired |
| US9051574B2 | Non-hemolytic ClyA for excretion of proteins | Emerging Cross-Sectional Technologies | 2 | Active |
| US8728760B2 | Microcin H47 plasmid selection system | Chemistry; Metallurgy | 2 | Active |
| US7125720B2 | Plasmid maintenance system for antigen delivery | Emerging Cross-Sectional Technologies | 2 | Expired |
| US7138112B2 | Plasmid maintenance system for antigen delivery | Emerging Cross-Sectional Technologies | 1 | Expired |
| US6977176B2 | Plasmid maintenance system for antigen delivery | Emerging Cross-Sectional Technologies | 1 | Expired |
| US8076130B2 | Plasmid maintenance system for antigen delivery | Chemistry; Metallurgy | 1 | Active |
| US11466075B2 | Yeast-based immunotherapy against clostridium difficile infection | Chemistry; Metallurgy | 1 | Active |
| US9446113B2 | Bacterial live vector vaccines expressing chromosomally-integrated foreign antigens | Emerging Cross-Sectional Technologies | 1 | Active |
| US9011871B2 | Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease | Emerging Cross-Sectional Technologies | 0 | Active |
| US9050283B2 | Broad spectrum vaccine against non-typhoidal Salmonella | Emerging Cross-Sectional Technologies | 0 | Active |
| US11744884B2 | Live Salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US10010596B2 | Bacterial live vector vaccines expressing chromosomally-integrated foreign antigens | Emerging Cross-Sectional Technologies | 0 | Active |
| US12384833B2 | Yeast-based immunotherapy against Clostridium difficile infection | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.